NPI registry status
Active
2026 NPPES data Hematology & Oncology Physician NPI 1518986538 M.D.
Verify on CMS → Nirmala Saraf, M.D.
Hematology & Oncology Physician in East Orange, New Jersey.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 11,530 in Hematology & Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
914
Medicare Part D claims · 64 beneficiaries · Hematology & Oncology Physician avg: 885
Generic prescribing
87%
generic claims · 13% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$1.4K
57 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Nirmala Saraf, M.D. filed 914 Medicare Part D claims in 2024 as a Hematology & Oncology Physician in East Orange, New Jersey, prescribing 87% generic.
- 914
- Part D claims, 2024
- 87%
- generic prescribing
- $1.4K
- industry payments (Sunshine Act)
- ≥74th
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Nirmala Saraf, M.D.
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1518986538), first enumerated 07/19/2006.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 914 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Practices in an ABMS-board-eligible specialty; board certification not confirmed in federal records.
- Reported
Industry payment transparency
$1.4K in reported industry payments (57 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1518986538 · Hematology & Oncology Physician
NPI-10 · ENUM-LEGACY · TAX-MID · RX-LIGHT · BOOK-THIN · PHOTO-ENUM
- NPI-10 1518986538
- ENUM-LEGACY 2006
- TAX-MID 12K Hematology &
- RX-LIGHT 914
- BOOK-THIN 333 in New Jersey
- PHOTO-ENUM Brenda Cooper · 2006
Nirmala Saraf, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
914 ≥ 74th percentile 74% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
◑
Board-eligible specialty (heuristic, not verified)
Nirmala Saraf, M.D. practices in an ABMS-board-eligible specialty but we don't have enough CMS-participation signals to confirm active board-certified status. Consult CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Nirmala Saraf, M.D.?
Quality data not reportedPrimary specialty
Hematology & Oncology Physician
Medicare Part D claims
914 3% vs specialty avg
Specialty distribution in New Jersey
How Hematology & Oncology Physician compares to other specialties among New Jersey providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Hematology & Oncology Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1518986538 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 07/19/2006 |
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Nirmala Saraf, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$1.4K
Largest payer
Janssen Biotech, Inc.
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
Brand vs generic prescribing mix · Typical
Nirmala Saraf, M.D. - brand share 13.0%
Hematology & Oncology Physician average
13% brand-name claims vs 87% generic, on 914 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
914
Total Claims
$491K
Total Drug Cost
64
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 1,239.233
- Total Day Supply
- 33,145
- Brand vs Generic
- 13% brand / 87% generic
- Brand Drug Cost
- $478K
- Generic Drug Cost
- $12K
- Opioid Claims
- 77 (8.4% rate)
- Antibiotic Claims
- 36
Patient Demographics
- Average Patient Age
- 73.7 years
- Avg HCC Risk Score
- 1.97
- Gender Split
- 69% female / 31% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Nirmala Saraf, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Amlodipine Besylate
Amlodipine Besylate
79 claims
- Pantoprazole Sodium
Pantoprazole Sodium
47 claims
- Eliquis
Eliquis
37 claims
- Albuterol Sulfate …
Albuterol Sulfate Hfa
36 claims
- Atorvastatin Calcium
Atorvastatin Calcium
33 claims
- Gabapentin
Gabapentin
33 claims
- Oxycodone-Acetamin… 29
Oxycodone-Acetaminophen
29 claims
- Tramadol Hcl 29
Tramadol Hcl
29 claims
| Drug | Claims |
|---|---|
| Amlodipine Besylate | 79 |
| Pantoprazole Sodium | 47 |
| Eliquis Apixaban | 37 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 36 |
| Atorvastatin Calcium | 33 |
| Gabapentin | 33 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 29 |
| Tramadol Hcl | 29 |
| Alendronate Sodium | 22 |
| Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide | 21 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How Nirmala Saraf, M.D. fits within the Hematology & Oncology Physician landscape nationally.
11,530
Hematology & Oncology Physician Providers in US
54
States with Hematology & Oncology Physician
885
Avg Claims per Provider
Nirmala Saraf, M.D.'s 914 claims are above the specialty average of 885.
Nationwide Hematology & Oncology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Saraf, both outside New Jersey so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2006)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Hematology & Oncology Physician Providers in New Jersey
Other clinicians with the same primary specialty enrolled in New Jersey, drawn from the same CMS NPPES roster as Saraf.
One of 333 Hematology & Oncology Physician providers enrolled in New Jersey, 5 are shown here.
Dr. Muhammad Abbasi
M.D.
Mountain Lakes, NJ
Dr. May Abdo-Matkiwsky
D.O.
Sparta, NJ
Dr. Stephen Abo
D.O.
Newark, NJ
Dr. Ahmed Abou Hussein
M.D.
Camden, NJ
Dr. Kenneth Adler
M.D,
Morristown, NJ
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Nirmala Saraf, M.D.'s specialty? ▼
Nirmala Saraf, M.D. specializes in Hematology & Oncology Physician and practices in East Orange, New Jersey. Credentials: M.D..
How much does Nirmala Saraf, M.D. prescribe under Medicare Part D? ▼
In 2024, Nirmala Saraf, M.D. wrote 914 Medicare Part D claims totaling $491K in drug costs for 64 beneficiaries.
Where is Nirmala Saraf, M.D. located? ▼
Nirmala Saraf, M.D. is located at 310 CENTRAL AVE, East Orange, NJ, 07018. Phone: (973) 395-1500.
What is Nirmala Saraf, M.D.'s NPI number? ▼
Nirmala Saraf, M.D.'s National Provider Identifier (NPI) is 1518986538, issued on 07/19/2006.
Does Nirmala Saraf, M.D. prescribe more brand-name or generic drugs? ▼
Nirmala Saraf, M.D.'s prescribing is 13% brand-name and 87% generic drugs by claim count, with $478K in brand drug costs.
Does Nirmala Saraf, M.D. prescribe opioids? ▼
Yes, Nirmala Saraf, M.D. had 77 opioid claims in 2024 with an opioid prescribing rate of 8.4%.
How many Hematology & Oncology Physician providers are there in the US? ▼
There are 11,530 Hematology & Oncology Physician providers across 54 states in the US. The average Hematology & Oncology Physician provider writes 885 Medicare Part D claims per year.
What drugs does Nirmala Saraf, M.D. prescribe most often? ▼
Based on 2024 Medicare Part D data, Nirmala Saraf, M.D.'s most frequently prescribed drugs include Amlodipine Besylate, Pantoprazole Sodium, Eliquis. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Nirmala Saraf, M.D. accept Medicare? ▼
Nirmala Saraf, M.D. appears in CMS Medicare data with 914 Part D claims and 64 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Nirmala Saraf, M.D.'s credentials? ▼
Nirmala Saraf, M.D.'s NPI is 1518986538 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.